Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024
|
EQS-News: Heidelberg Pharma AG
/ Key word(s): Conference
PRESS RELEASE Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024 Ladenburg, Germany, 6 November 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from 7-10 December 2024 in San Diego, California, USA. Robert Z. Orlowski, MD, PhD, (Ad Interim) Director of Myeloma and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, University of Texas, Houston, Texas, and principal investigator at MD Anderson Cancer Center, Houston, Texas, USA, will report the latest developments from the ongoing Phase I/IIa study of HDP-101 for the treatment of relapsed or refractory multiple myeloma. Currently advancing in its sixth cohort, the study has shown encouraging results, including complete remission in one patient from the fifth cohort who had been previously treated multiple times and had received several courses of HDP-101. In addition, several patients showed promising biological activity and objective improvements, underscoring the potential of HDP-101 as a treatment option for patients with this disease. 66th American Society of Hematology (ASH) Annual Meeting
In October, Robert Z. Orlowski, MD, PhD, along with Heidelberg Pharma's Chief Medical Officer, András Strassz, and another Key Opinion Leader (KOL) in the field of Myeloma, discussed the progress of the dose escalation study of HDP-101 during a R&D webinar. Robert Z. Orlowski commented, “I would say that this should be considered a great drug for all relapsed or refractory myelomas.” The recording of the R&D webinar can be found here: Virtual KOL Event on Multiple Myeloma and Updated Clinical Data from the IMS Oral Presentation of HDP-101, an Anti-BCMA ADC About Heidelberg Pharma Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells. Heidelberg Pharma uses several compounds and has built up an ADC toolbox that overcomes tumor resistance via numerous pathways and addresses different types of cancer using various antibodies. The goal is to develop targeted and highly effective ADCs for the treatment of a variety of malignant hematologic and solid tumors. Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology. It offers the opportunity to overcome therapy resistance and also eliminate dormant tumor cells, which could lead to significant progress in cancer therapy - even for patients who no longer respond to other treatment. The most advanced product candidate HDP-101 is a BCMA-ATAC for the indication multiple myeloma, which is currently in clinical development. The first candidate that Heidelberg Pharma is developing with a toxin other than Amanitin is HDP-201, an Exatecan-based ADC. Exatecan is a topoisomerase I inhibitor that has proven itself in cancer therapy and is used in two already approved ADCs. It differs in its mode of action from that of Amanitin and thus expands the company's range of compounds. The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com. ATAC® is a registered trademark of Heidelberg Pharma Research GmbH. ITAC™, ETAC™ are pending trademark applications of Heidelberg Pharma Research GmbH.
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will”, "should”, "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
06.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
||||||||||||||
| Language: | English |
| Company: | Heidelberg Pharma AG |
| Gregor-Mendel-Str. 22 | |
| 68526 Ladenburg | |
| Germany | |
| Phone: | +49 (0)89 41 31 38 - 0 |
| Fax: | +49 (0)89 41 31 38 - 99 |
| E-mail: | investors@hdpharma.com |
| Internet: | www.heidelberg-pharma.com |
| ISIN: | DE000A11QVV0 |
| WKN: | A11QVV |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2023707 |
| End of News | EQS News Service |
|
|
2023707 06.11.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
Die hier dargestellten Informationen wurden von unserem Content-Partner EQS-Group bereitgestellt. Urheber4 der Nachricht ist der jeweilige Emittent, das die Nachricht betreffende Unternehmen, ein Publikationsdienstleister (Presse- oder Informationsagentur), welche(r) den Distributionsservice3 der EQS nutzt, um Unternehmensnachrichten an Aktionäre, Investoren, Anleger oder Interessenten zu übermitteln. Die Originalpublikationen sowie weitere Unternehmensrelevante Informationen finden Sie auf eqs-news.com.
Die Informationsangebote die Sie abrufen können, stellen keine Anlageberatung dar. Die Vorstellung unserer Kooperationspartner, bei denen die Umsetzung von Anlageentscheidungen je nach individuellem Risikoprofil möglich wäre, liegt allein im Ermessen desjenigen, der den Service in Anspruch nimmt. Wir stellen ausschließlich Unternehmen vor, von denen wir überzeugt sind, dass Leistungsangebot und Kundenservice anspruchsvollen Anlegern gerecht werden.
Sollten Sie Hebelprodukte in Erwägung ziehen, machen Sie sich zuvor mit den typischen Eigenschaften der Finanzinstrumente vertraut. Nehmen Sie sich die Zeit, den Risikogehalt der geplanten Investition m Vorfeld einer Anlageentscheidung zu bestimmen. Bedenken Sie, dass bei Hebelprodukten auch ein Totalverlust nicht ausgeschlossen werden kann.
Für Einsteiger in die Materie bieten wir sowohl in der Weiterbildungs- als auch in der Tools-Sektion verschiedene Möglichkeiten an, über die Sie theoretische Kenntnisse und praxisnahe Erfahrungen trainieren und somit Ihre Fertigkeiten verbessern können. Das Angebot reicht von der Teilnahme an Webinaren bis hin zum persönlichen Mentoring. Der Bereich wird kontinuierlich erweitert.
1 Lab Features sind in der Regel Funktionalitäten, die aus der Ideenschmiede der Anleger-Community heraus entstehen. Im frühen Stadium handelt es sich dabei um experimentelle Funktionalitäten, deren Entwicklungsprozess maßgeblich durch Nutzung und daraus abgeleiteten Feedback seitens der Community bestimmt wird. Bei der Einbindung externer Services oder Funktionalitäten kann die Funktionsweise nur soweit gewährleistet werden, wie die einzelnen Prozesselemente wie bspw. Schnittstellen miteinander interagieren.
2 Die genannten Finanzprodukte sind mit hohen Risiken und Schließen die Möglichkeit eines Totalverlustes nicht aus.
3 Die EQS Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.
4 Vom Urheberrecht erfasst sind Bild-, Logo-, Markenrechte sowie über die News übermitteltes Bildmaterial. Für in die Nachrichten eingebettete Inhalte Dritter, Verlinkungen zu externen Seiten oder Dokumenten ist der Ersteller der Publikation verantwortlich.